Advanced Pharmacology Fundamentals for Care of
the Family Review| Q&A| Grade A| 100% Correct
(Verified Solutions)- Chamberlain
Q. 1) In CKD, first-line agents to reduce proteinuria and slow progression are:
ANSWER
B. ACE inhibitors or ARBs
Q. 2) The electrolyte abnormality most responsible for malignant ventricular arrhythmia risk in CKD is:
ANSWER
B. Hyperkalemia
Q. 3) Which complication of CKD is primarily due to reduced erythropoietin production?
ANSWER
B. Anemia
Q. 4) Uremic pericarditis in CKD results from:
ANSWER
B. Accumulated nitrogenous wastes
Q. 5) The major driver of secondary hyperparathyroidism in CKD is:
ANSWER
B. Hyperphosphatemia with low calcitriol
Q. 6) Sodium handling in CKD is impaired. A common downstream clinical effect is:
ANSWER
B. Hypertension and edema
1
,Q. 7) Appropriate first step when starting epoetin alfa for CKD anemia:
ANSWER
B. Ensure iron sufficiency and check ferritin and TSAT
Q. 8) Black box warning for epoetin alfa includes increased risk of:
ANSWER
B. Venous thromboembolism, MI, stroke, and death
Q. 9) Which is a contraindication to epoetin alfa initiation in CKD?
ANSWER
B. Uncontrolled hypertension
Q. 10) The earliest expected lab change after starting epoetin alfa is:
ANSWER
B. Reticulocytosis within about 10 days
Q. 11) Best counseling for epoetin alfa storage and handling:
ANSWER
C. Do not shake. Protect from light
Q. 12) Sodium polystyrene sulfonate decreases serum potassium primarily by:
ANSWER
C. Cation exchange in the gut with fecal K+ elimination
Q. 13) A serious GI adverse effect associated with SPS is:
ANSWER
B. Ischemic colitis and colonic necrosis
2
,Q. 14) Avoid coadministration of SPS with which agent because of increased colonic injury risk:
ANSWER
A. Sorbitol
Q. 15) SPS should be avoided in:
ANSWER
B. Obstructive bowel disease
Q. 16) Calcium acetate lowers phosphate by:
ANSWER
B. Binding dietary phosphate in the gut
Q. 17) Key on-therapy risk with calcium acetate in ESRD:
ANSWER
B. Hypercalcemia and vascular calcification
Q. 18) Which drug's absorption can be reduced by calcium acetate binding?
ANSWER
A. Levothyroxine
Q. 19) Dose timing advice for calcium acetate:
ANSWER
B. Take with meals
Q. 20) Cinacalcet mechanism of action is best described as:
ANSWER
B. Calcimimetic increasing CaSR sensitivity to Ca
3
, Q. 21) The most common adverse effect with cinacalcet is:
ANSWER
B. Nausea and vomiting
Q. 22) Absolute contraindication for cinacalcet:
ANSWER
A. Severe hypocalcemia
Q. 23) Key interaction that raises cinacalcet levels:
ANSWER
B. Ketoconazole
Q. 24) Which lab should be checked within one week of cinacalcet initiation or dose change?
ANSWER
B. Serum calcium
Q. 25) Phenazopyridine provides:
ANSWER
B. Local urinary analgesia with discoloration of urine
Q. 26) A key counseling point with phenazopyridine is:
ANSWER
B. Urine and tears may turn orange or red
Q. 27) Phenazopyridine is relatively contraindicated during breastfeeding due to risk of:
ANSWER
B. Methemoglobinemia and hemolysis, especially in G6PD deficiency
4